In a global analysis, GAFFI has identified major gaps in antifungal drug provision for common fungal infections. From multiple sources—most directly from individual countries—it shows flucytosine availability in 24% (map), amphotericin B deoxycholate in 49% (map), itraconazole in 93% (map) and fluconazole in 98% (map) of countries (including PEPFAR provision). No vital antifungals are available… Read more »